[go: up one dir, main page]

MX2021008039A - Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido. - Google Patents

Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido.

Info

Publication number
MX2021008039A
MX2021008039A MX2021008039A MX2021008039A MX2021008039A MX 2021008039 A MX2021008039 A MX 2021008039A MX 2021008039 A MX2021008039 A MX 2021008039A MX 2021008039 A MX2021008039 A MX 2021008039A MX 2021008039 A MX2021008039 A MX 2021008039A
Authority
MX
Mexico
Prior art keywords
quinoxaline
substituted
polymorphic forms
piperidine compound
type bridged
Prior art date
Application number
MX2021008039A
Other languages
English (en)
Inventor
Naoki Tsuno
Naoki Miyake
Ronnie Ortiz
David Igo
Mayu Fukuda
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MX2021008039A publication Critical patent/MX2021008039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan formas cristalinas novedosas de un compuesto cristalino de la Fórmula (I), que modula el receptor ORL-1. Los compuestos cristalinos de la Fórmula (I), composiciones de estos y métodos para su uso que se describen en la presente son particularmente útiles para el tratamiento, la prevención y la gestión de diversos trastornos del sueño.
MX2021008039A 2019-01-31 2020-01-30 Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido. MX2021008039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799710P 2019-01-31 2019-01-31
PCT/IB2020/050741 WO2020157691A1 (en) 2019-01-31 2020-01-30 Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound

Publications (1)

Publication Number Publication Date
MX2021008039A true MX2021008039A (es) 2021-08-05

Family

ID=69528888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008039A MX2021008039A (es) 2019-01-31 2020-01-30 Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido.

Country Status (14)

Country Link
US (2) US12371427B2 (es)
EP (1) EP3917621A1 (es)
JP (2) JP7709916B2 (es)
KR (1) KR102659846B1 (es)
CN (1) CN113301957A (es)
AU (2) AU2020213989B2 (es)
BR (1) BR112021010184A2 (es)
IL (1) IL284564B2 (es)
MX (1) MX2021008039A (es)
PH (1) PH12021551794A1 (es)
SG (1) SG11202107481TA (es)
UA (1) UA126880C2 (es)
WO (1) WO2020157691A1 (es)
ZA (1) ZA202106145B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013514A (es) 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
JP5554709B2 (ja) 2007-08-31 2014-07-23 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプピペリジン化合物とその使用
EA021792B1 (ru) 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
WO2010010458A1 (en) 2008-07-21 2010-01-28 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم

Also Published As

Publication number Publication date
WO2020157691A1 (en) 2020-08-06
PH12021551794A1 (en) 2022-03-21
AU2023203345A1 (en) 2023-06-22
NZ776717A (en) 2024-09-27
IL284564B1 (en) 2025-03-01
CN113301957A (zh) 2021-08-24
US20220098186A1 (en) 2022-03-31
EP3917621A1 (en) 2021-12-08
KR20210087493A (ko) 2021-07-12
US12371427B2 (en) 2025-07-29
IL284564B2 (en) 2025-07-01
AU2020213989A1 (en) 2021-06-17
JP2022519231A (ja) 2022-03-22
US20260022115A1 (en) 2026-01-22
IL284564A (en) 2021-08-31
SG11202107481TA (en) 2021-08-30
BR112021010184A2 (pt) 2021-08-17
KR102659846B1 (ko) 2024-04-24
UA126880C2 (uk) 2023-02-15
AU2020213989B2 (en) 2023-06-15
JP2023116756A (ja) 2023-08-22
ZA202106145B (en) 2025-04-30
JP7709916B2 (ja) 2025-07-17
CA3127469A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CL2020001546A1 (es) Compuestos de 4-azaindol.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2017012594A2 (es) Moduladores de receptor nuclear
ECSP10010657A (es) Nuevos compuestos tricíclicos
DOP2021000088A (es) Compuestos de azalactam como inhibidores de hpk1
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
BR112018006259A2 (pt) &#34;adjunto compressível com estruturas de suporte intermediárias&#34;
CR20120294A (es) Compuestos tricíclicos novedosos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
CL2019002919A1 (es) Compuestos inhibidores vmat2 y composiciones relacionadas.
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
CL2022001950A1 (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
CO6300898A2 (es) Sales y polimorfos de 9-(2,2-dimetil-propil-aminometil)-minociclina
CL2021001461A1 (es) Moduladores de trex1
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CO2022000186A2 (es) Nuevos compuestos heterocíclicos